242 related articles for article (PubMed ID: 16252135)
21. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
22. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Shepard RC; Levy DE; Berlin JD; Stuart K; Harris JE; Aviles V; Thomas JP; Benson AB
Oncology; 2004; 66(4):303-9. PubMed ID: 15218298
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K
Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445
[TBL] [Abstract][Full Text] [Related]
26. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Wolff RA; Evans DB; Gravel DM; Lenzi R; Pisters PW; Lee JE; Janjan NA; Charnsangavej C; Abbruzzese JL
Clin Cancer Res; 2001 Aug; 7(8):2246-53. PubMed ID: 11489798
[TBL] [Abstract][Full Text] [Related]
28. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Haddock MG; Swaminathan R; Foster NR; Hauge MD; Martenson JA; Camoriano JK; Stella PJ; Tenglin RC; Schaefer PL; Moore DF; Alberts SR
J Clin Oncol; 2007 Jun; 25(18):2567-72. PubMed ID: 17577035
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
32. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E
Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
Epelbaum R; Rosenblatt E; Nasrallah S; Faraggi D; Gaitini D; Mizrahi S; Kuten A
J Surg Oncol; 2002 Nov; 81(3):138-43. PubMed ID: 12407726
[TBL] [Abstract][Full Text] [Related]
34. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
35. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
36. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Aitini E; Marangolo M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):51-7. PubMed ID: 16767907
[TBL] [Abstract][Full Text] [Related]
37. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Jacobs AD; Otero H; Picozzi VJ; Aboulafia DM
Cancer Invest; 2004; 22(4):505-14. PubMed ID: 15565807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
